Drug Search Results
Using advanced filters...
Advanced Search [+]

Opebacan

Alternative Names: opebacan
Latest Update: 2019-11-20
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Gram- Bacteria Degrader

Novel Mechanism: Yes

Modality: Coagulation Factor

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: XOMA
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Burns Unspecified|Graft vs Host Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

HSCT

P2

Terminated

Graft vs Host Disease

2010-06-01

XO-400761

P2

Terminated

Burns Unspecified

2007-11-01

Recent News Events

Date

Type

Title